M.E. Rinella, J.V. Lazarus, V. Ratziu, S.M. Francque, A.J. Sanyal, F. Kanwal, D. Romero, M.F. Abdelmalek, Q.M. Anstee, J.P. Arab, M. Arrese, R. Bataller, U. Beuers, J. Boursier, E. Bugianesi, C.D. Byrne, G.E. Castro Narro, A. Chowdhury, H. Cortez-Pinto, D.R. Cryer, K. Cusi, M. El-Kassas, S. Klein, W. Eskridge, J. Fan, S. Gawrieh, C.D. Guy, S.A. Harrison, S.U. Kim, B.G. Koot, M. Korenjak, K.V. Kowdley, F. Lacaille, R. Loomba, R. Mitchell-Thain, T.R. Morgan, E.E. Powell, M. Roden, M. Romero-Gomez, M. Silva, S.P. Singh, S.C. Sookoian, C.W. Spearman, D. Tiniakos, L. Valenti, M.B. Vos, V.W. Wong, S. Xanthakos, Y. Yilmaz, Z. Younossi, A. Hobbs, Villota-Rivas, P.N. Newsome, N.N.c. group, A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 78, 1966–1986 (2023)

Article  PubMed  Google Scholar 

E. Makri, A. Goulas, S.A. Polyzos, Epidemiology, Pathogenesis, diagnosis and emerging treatment of nonalcoholic fatty liver disease. Arch. Med. Res. 52, 25–37 (2021)

Article  PubMed  CAS  Google Scholar 

S.A. Polyzos, G. Targher, Hepatic thyroid hormone receptor-beta signalling: mechanisms and recent advancements in the treatment of metabolic dysfunction-associated steatohepatitis. Diabetes Obes. Metab. 27, 1635–1647 (2025)

Article  PubMed  CAS  Google Scholar 

S.A. Polyzos, C.S. Mantzoros, Metabolic dysfunction-associated steatotic liver disease: recent turning points for its diagnosis and management. Metabolism. 157, 155936 (2024)

Article  PubMed  CAS  Google Scholar 

A.J. Sanyal, P.N. Newsome, I. Kliers, L.H. Ostergaard, M.T. Long, M.S. Kjaer, A.M.G. Cali, E. Bugianesi, M.E. Rinella, M. Roden, V. Ratziu, E.S. Group, Phase 3 trial of semaglutide in metabolic Dysfunction-Associated steatohepatitis. N Engl. J. Med. 392, 2089–2099 (2025)

Article  PubMed  CAS  Google Scholar 

S.A. Polyzos, J. Kountouras, C. Zavos. The multi-hit process and the antagonistic roles of tumor necrosis factor-alpha and adiponectin in non alcoholic fatty liver disease. Hippokratia. 13, 127; author reply 128 (2009)

PubMed  PubMed Central  CAS  Google Scholar 

S.A. Polyzos, D.G. Goulis, Menopause and metabolic dysfunction-associated steatotic liver disease. Maturitas. 186, 108024 (2024)

Article  PubMed  CAS  Google Scholar 

A. Jaroenlapnopparat, N. Charoenngam, B. Ponvilawan, M. Mariano, J. Thongpiya, P. Yingchoncharoen, Menopause is associated with increased prevalence of nonalcoholic fatty liver disease: a systematic review and meta-analysis. Menopause. 30, 348–354 (2023)

Article  PubMed  Google Scholar 

C. Allaire, M.A. Bedaiwy, P.J. Yong, Diagnosis and management of endometriosis. CMAJ. 195, E363–E371 (2023)

Article  PubMed  PubMed Central  Google Scholar 

G.A. Dunselman, N. Vermeulen, C. Becker, C. Calhaz-Jorge, T. D’Hooghe, B. De Bie, O. Heikinheimo, A.W. Horne, L. Kiesel, A. Nap, A. Prentice, E. Saridogan, D. Soriano, W. Nelen, European society of Human, Embryology, ESHRE guideline: management of women with endometriosis. Hum. Reprod. 29, 400–412 (2014)

Article  PubMed  CAS  Google Scholar 

A.D. Anastasilakis, S. Papachatzopoulos, P. Makras, A. Gkiomisi, P. Nikolakopoulos, S.A. Polyzos, C. Ntenti, I. Ballaouri, S. Gerou, O. Tsachouridou, A. Papatheodorou, K. Aliazis, S. Fermanoglou, I. Bisbinas, M.P. Yavropoulou, The effect of Pharmacological cessation and restoration of menstrual cycle on bone metabolism in premenopausal women with endometriosis. Bone. 158, 116354 (2022)

Article  PubMed  CAS  Google Scholar 

L. Gong, S. Zhang, Y. Han, Q. Long, S. Zou, Y. Cao, Initiation of GnRH agonist treatment on 3–5 days postoperatively in endometriosis patients: a randomized controlled trial. J. Clin. Pharmacol. 55, 848–853 (2015)

Article  PubMed  CAS  Google Scholar 

A.D. Anastasilakis, S.A. Polyzos, P.A. Vorkas, A. Gkiomisi, M.P. Yavropoulou, M. Rauner, P. Nikolakopoulos, S. Papachatzopoulos, P. Makras, S. Gerou, L.C. Hofbauer, A. Palermo, E. Tsourdi, Lipid profile after Pharmacologic discontinuation and restoration of menstruation in women with endometriosis: A 12-Month observational prospective study. J. Clin. Med. 12, 5430 (2023)

Article  PubMed  PubMed Central  CAS  Google Scholar 

J.H. Lee, D. Kim, H.J. Kim, C.H. Lee, J.I. Yang, W. Kim, Y.J. Kim, J.H. Yoon, S.H. Cho, M.W. Sung, H.S. Lee, Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease. Dig. Liver Dis. 42, 503–508 (2010)

Article  PubMed  CAS  Google Scholar 

S. Zhang, T. Du, J. Zhang, H. Lu, X. Lin, J. Xie, Y. Yang, X. Yu, The triglyceride and glucose index (TyG) is an effective biomarker to identify nonalcoholic fatty liver disease. Lipids Health Dis. 16, 15 (2017)

Article  PubMed  PubMed Central  Google Scholar 

S. Zhang, T. Du, M. Li, J. Jia, H. Lu, X. Lin, X. Yu. Triglyceride glucose-body mass index is effective in identifying nonalcoholic fatty liver disease in nonobese subjects. Medicine (Baltimore). 96, e7041 (2017)

Article  PubMed  CAS  Google Scholar 

Y. Fukuda, Y. Hashimoto, M. Hamaguchi, T. Fukuda, N. Nakamura, A. Ohbora, T. Kato, T. Kojima, M. Fukui, Triglycerides to high-density lipoprotein cholesterol ratio is an independent predictor of incident fatty liver; a population-based cohort study. Liver Int. 36, 713–720 (2016)

Article  PubMed  CAS  Google Scholar 

J.H. Lee, K. Park, H.S. Lee, H.K. Park, J.H. Han, S.B. Ahn, The usefulness of metabolic score for insulin resistance for the prediction of incident non-alcoholic fatty liver disease in Korean adults. Clin. Mol. Hepatol. 28, 814–826 (2022)

Article  PubMed  PubMed Central  Google Scholar 

S. McHenry, Y. Park, J.D. Browning, G. Sayuk, N.O. Davidson, Dallas steatosis index identifies patients with nonalcoholic fatty liver disease. Clin. Gastroenterol. Hepatol. 18, 2073–2080 (2020)

Article  PubMed  PubMed Central  CAS  Google Scholar 

M.T. Long, A. Pedley, L.D. Colantonio, J.M. Massaro, U. Hoffmann, P. Muntner, C.S. Fox. Development and Validation of the Framingham Steatosis Index to Identify Persons With Hepatic Steatosis. Clin Gastroenterol Hepatol. 14, 1172–1180 e1172 (2016)

S.A. Harrison, D. Oliver, H.L. Arnold, S. Gogia, B.A. Neuschwander-Tetri, Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut. 57, 1441–1447 (2008)

Article  PubMed  CAS  Google Scholar 

Y. Sasaki, H. Kajino, H. Gotoda, A case of nonalcoholic steatohepatitis in central precocious puberty aggravated by Gonadotropin-releasing hormone analog. JPGN Rep. 1, e014 (2020)

Article  PubMed  PubMed Central  Google Scholar 

P. Gild, A.P. Cole, A. Krasnova, B.A. Dickerman, N. von Landenberg, M. Sun, L.A. Mucci, S.R. Lipsitz, F.K. Chun, P.L. Nguyen, A.S. Kibel, T.K. Choueiri, S. Basaria, Q.D. Trinh, Liver disease in men undergoing androgen deprivation therapy for prostate cancer. J. Urol. 200, 573–581 (2018)

Article  PubMed  CAS  Google Scholar 

C. Gabbi, F. Carubbi, L. Losi, P. Loria, M. Costantini, M. Bertolotti, N. Carulli, Nonalcoholic fatty liver disease induced by leuprorelin acetate. J. Clin. Gastroenterol. 42, 107–110 (2008)

Article  PubMed  Google Scholar 

H. Sawazaki, Y. Kitamura, K. Yagi, Y. Arai, Impact of androgen deprivation therapy on Non-Alcoholic fatty liver disease in patients with prostate cancer: A CT evaluation. Urol. Int. 104, 425–430 (2020)

Article  PubMed  Google Scholar 

H. Huang, Z. Liu, J. Ruan, Z. Fang, C. Xu, Laparoscopically confirmed endometriosis and the risk of incident NAFLD: a prospective cohort study. Reprod. Biol. Endocrinol. 23, 55 (2025)

Article  PubMed  PubMed Central  CAS  Google Scholar 

E.S. Makri, E. Makri, S.A. Polyzos, Combination therapies for nonalcoholic fatty liver disease. J. Pers. Med. 12, 1166 (2022)

Article  PubMed  PubMed Central  Google Scholar